Results 91 to 100 of about 6,578,993 (340)

Multiple myeloma current treatment algorithms

open access: yesBlood Cancer Journal, 2020
The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple new drugs, and emerging data from randomized trials to guide therapy.
S. Rajkumar, Shaji K. Kumar
semanticscholar   +1 more source

BCR::ABL1‐Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B‐ALL Cells to Enhancer‐Targeting Drugs

open access: yesAdvanced Science, EarlyView.
Ng et al. show that the BCR::ABL1 kinase that drives the lymphoid leukemia Ph+B‐ALL modulates enhancer function by coopting signaling‐inducible transcription factors such as MYC, STAT5, and ETV5. BCR::ABL1 thereby promotes the transcriptional program driving and defining this leukemia and renders Ph+B‐ALL cells hypersensitive to enhancer‐inhibiting ...
Han Leng Ng   +19 more
wiley   +1 more source

The non-coding RNA landscape of plasma cell dyscrasias [PDF]

open access: yes, 2020
Despite substantial advancements have been done in the understanding of the pathogenesis of plasma cell (PC) disorders, these malignancies remain hard-to-treat.
Azab, Kareem A   +3 more
core   +1 more source

Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease [PDF]

open access: yes, 2014
Multiple myeloma (MM) is the second most common haematological malignancy and results in destructive bone lesions. The interaction between MM cells and the bone microenvironment plays an important role in the development of the tumour cells and MM ...
Blum B   +6 more
core   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

open access: yesAdvanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey   +6 more
wiley   +1 more source

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

open access: yesFrontiers in Immunology, 2018
The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM ...
Shih-Feng Cho   +7 more
doaj   +1 more source

Proteasome Inhibitors for the Treatment of Multiple Myeloma

open access: yesCancers, 2020
Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment over the past decade. Many PIs are being developed and evaluated in the preclinical and clinical setting.
S. Ito
semanticscholar   +1 more source

Tetrastigma Hemsleyanum Polysaccharide Suppresses Triple‐Negative Breast Cancer by Disrupting the Hippo‐YAP/TEAD4‐PDIA4 Axis and Endoplasmic Reticulum Stress Adaptation

open access: yesAdvanced Science, EarlyView.
ABSTRACT Triple‐negative breast cancer (TNBC) exhibits addiction to chronic endoplasmic reticulum (ER) stress, which sustains an aggressive metastatic phenotype through activation of the unfolded protein response (UPR). Here, we identify a previously unrecognized “ER‐stress addiction” axis in which the Hippo pathway effector TEAD4 directly ...
Yini Shang   +9 more
wiley   +1 more source

Multiple Myeloma in Indonesia [PDF]

open access: yes, 2011
Tujuan: Melihat karakteristik klinis pasien mieloma multipel di Indonesia.Metode: studi deskriptif, potong lintang, multisenter, dilakukan pada November 2008 sampai dengan November 2009.
Reksodiputro, A. H. (Arry)   +2 more
core  

A metastatic secretory gastric plasmacytoma with aberrant CD3 expression in a dog [PDF]

open access: yes, 2017
A 10-year-old crossbred dog was presented with a 6-week history of hematemesis, melena, anorexia, and lethargy. Clinical evaluation revealed a gastric mass with a regional lymphadenomegaly as well as a monoclonal gammopathy manifesting as ...
Atherton, Matthew J.   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy